Separate terms with OR to return results that match either term.
 
Clear All

628 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status (Descending)
C9287 Brentuximab vedotin Adcetris 1 mg Immunotherapy Drug Antibody Conjugate CD30 No 2011 Jan. 1, 2012 Dec. 31, 2012 No Longer Used
C9215 Cetuximab Erbitux 10 mg Immunotherapy Monoclonal Antibody EGFR No 2004 Feb. 12, 2004 Dec. 31, 2004 No Longer Used
C9477 Elotuzumab Empliciti 1 mg Immunotherapy Monoclonal Antibody SLAMF7 No 2015 July 1, 2016 Dec. 31, 2016 No Longer Used
C9004 Gemtuzumab ozogamicin Mylotarg 5 mg Immunotherapy Drug Antibody Conjugate CD33 No 2000 Jan. 1, 2004 Dec. 31, 2005 No Longer Used
C9117 Ibritumomab tiuxetan Zevalin Per MCI Immunotherapy Radioimmunotherapy CD20 No 2002 Oct. 1, 2002 Dec. 31, 2002 No Longer Used
C9118 Ibritumomab tiuxetan Zevalin Per MCI Immunotherapy Radioimmunotherapy CD20 No 2002 Oct. 1, 2002 Dec. 31, 2002 No Longer Used
C9284 Ipilimumab Yervoy 1mg Immunotherapy Checkpoint Inhibitor CTLA-4 No 2011 July 1, 2011 Dec. 31, 2011 No Longer Used
C9021 Obinutuzumab Gazyva 10 mg Immunotherapy Monoclonal Antibody CD20 No 2013 April 4, 2014 Dec. 31, 2014 No Longer Used
C9260 Ofatumumab Arzerra 10mg Immunotherapy Monoclonal Antibody CD20 No 2009 April 1, 2010 Dec. 31, 2010 No Longer Used
C9235 Panitumumab Vectibix 10mg Immunotherapy Monoclonal Antibody EGFR No 2006 Jan. 1, 2007 Dec. 31, 2007 No Longer Used

Found 628 results in 2 millisecondsExport these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.